



FOR IMMEDIATE RELEASE ON March 10, 2025

Flamma Selected For 2025 CDMO Leadership Awards

Chignolo D'Isola, Bergamo, Italy – March 10, 2025 – The **Flamma Group** (“Flamma”), a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry as well as a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, is proud to announce that it has received a 2025 CDMO Leadership Award that will be presented in New York City on March 19, 2025.

Now in its 14th year, Outsourced Pharma’s CDMO Leadership Awards uses real customer data to evaluate various strengths and weaknesses of CDMOs. This year, almost 300 survey respondents evaluated 210 CDMOs. It should be noted that the respondents based their evaluations on companies with which they have worked on an outsourced project within the past 24 months.

An enhanced scoring methodology was developed in collaboration with Outsourced Pharma’s research partner, Orientation Marketing. This methodology was applied to four categories Small Molecule API, Biologics, Cell & Gene Therapy, and Small Molecule Dosage Form. The four categories were then further divided to recognize top CDMOs in three service regions: Global, North American, and International.

Flamma has been recognized as a 2025 CDMO Leadership Awards winner in the **Small Molecule API – Global** category. You can learn more as well as see the other award winners at <https://www.cmoleadershipawards.com>

“Flamma would like to express strong gratitude to Outsourced Pharma for continuing to shine a light and recognizing deserving CDMOs for their tireless work to help innovator companies in Biotech and Pharma who are trying to bring new medicines to the world,” noted Kenneth Drew, Ph.D., VP Flamma USA. “As Flamma celebrates 75 years of service to the industry, we strive to be a good partners. We obviously could not be selected without those customers who took the time to complete the survey and we thank all whom participated. Our passion continues and we will continue to work at an award winning level always.”

Flamma will proudly accept the awards at the CDMO Leadership Awards Ceremony and Reception on March 19, 2025 at the POOL in New York City.



Contact Flamma

Kenneth Drew, Ph.D., VP Flamma USA

1-617-515-0975

ken.drew@flammagroup.com

About Flamma:

FLAMMA is a family owned & run, fully integrated CDMO based in Bergamo (near Milan in Northern Italy) established in 1950.

FLAMMA is a company specialized in the cGMP manufacture of small molecule APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.

FLAMMA has five manufacturing facilities- Italy (3), China, and the USA. The cGMP Italian locations (Chignolo, Isso and Bulciago) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, is a cGMP manufacturing facility that has been inspected by Chinese National Medical Products Administration (NMPA) formally known as the Chinese FDA. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer's compound on-time and with the desired specifications. Flamma offers cost-effective services to customers looking for a trusted partner within China.

Flamma USA (Malvern, PA near Philadelphia) services customers looking to keep their pre-clinical/early stage clinical small molecule drug development in the USA. Flamma USA also offers the ability to handle HPAPIs as well as low volume commercial materials.

As a fully integrated company, Flamma can move customer compounds quickly along their journey by taking into consideration all aspects necessary for the success of customer's projects while providing supply chain security.



Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 1,100 m³ and over ~1,000 employees, see why Flamma should be your next contract manufacturer.

FLAMMA - THE THINKING CDMO™.

<https://www.flammagroup.com/>

<https://www.linkedin.com/company/flamma-spa/>

<https://twitter.com/flammagroup>

<https://www.facebook.com/TheFlammaGroup/>